Interpace Biosciences (STU:PF42) 3-Year Revenue Growth Rate : 4.60% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences 3-Year Revenue Growth Rate?

Interpace Biosciences's Revenue per Share for the three months ended in Mar. 2024 was €2.16.

During the past 12 months, Interpace Biosciences's average Revenue per Share Growth Rate was -8.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 4.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 3.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -27.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Interpace Biosciences was 64.70% per year. The lowest was -79.20% per year. And the median was -4.05% per year.

Competitive Comparison of Interpace Biosciences's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Interpace Biosciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Interpace Biosciences's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's 3-Year Revenue Growth Rate falls into.

Interpace Biosciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Interpace Biosciences (STU:PF42) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Interpace Biosciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (STU:PF42) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

IDXG:USA

Address

300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines